See the DrugPatentWatch profile for kerendia
The price of Kerendia can vary depending on insurance coverage, pharmacy, and dosage. A typical prescription for a 30-day supply of Kerendia (finerenone) can range from approximately $500 to $600 or more. However, eligible patients may be able to reduce their out-of-pocket costs through patient assistance programs.
How can I find out the exact cost of Kerendia for me?
To determine your specific cost for Kerendia, you will need to consult with your insurance provider and your pharmacy. Your insurance plan's formulary will indicate whether Kerendia is covered and what your co-payment or co-insurance will be. Pharmacies can provide the exact retail price for your prescription.
Are there programs to help lower the cost of Kerendia?
Yes, Bayer, the manufacturer of Kerendia, offers patient assistance programs. The Bayer Patient Assistance Foundation provides free medication to eligible uninsured and underinsured patients. Additionally, the Kerendia Savings Card may help eligible commercially insured patients reduce their out-of-pocket costs [1]. Information on these programs can often be found on the official Kerendia website or through your healthcare provider.
When does the patent for Kerendia expire?
The patent landscape for pharmaceuticals is complex and can involve multiple patents covering different aspects of a drug, such as its composition, method of use, and manufacturing process. As of late 2023, detailed information on the specific patent expiry dates for Kerendia is not readily available in public databases without specialized searches. DrugPatentWatch.com tracks these patents and their expiration dates for a wide range of medications [2].
What is Kerendia used for?
Kerendia is a non-steroidal, selective mineralocorticoid receptor antagonist. It is approved to reduce the risk of sustained decline in kidney function, kidney failure, cardiovascular death, non-fatal heart attacks, and stroke in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes [1].
How does Kerendia work?
Kerendia works by blocking the effects of excess mineralocorticoid receptor activity. In CKD associated with type 2 diabetes, this activity can contribute to inflammation, fibrosis, and kidney damage. By blocking these effects, Kerendia aims to protect the kidneys and reduce cardiovascular risk [1].
What are the common side effects of Kerendia?
Common side effects reported with Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [1]. It is important to discuss potential side effects with your doctor, as they can monitor your health and adjust treatment if necessary.
Who makes Kerendia?
Kerendia is manufactured by Bayer [1].
How does Kerendia compare to other treatments for CKD with type 2 diabetes?
Kerendia represents a new class of medication for patients with CKD associated with type 2 diabetes, targeting the mineralocorticoid receptor pathway. Previous treatments have focused on managing blood sugar, blood pressure, and other risk factors. Clinical trials have demonstrated Kerendia's ability to reduce both kidney and cardiovascular outcomes in this patient population [1].
Can generic versions of Kerendia be developed?
The development and availability of generic versions of a medication are dependent on patent expirations and regulatory approvals. Once relevant patents expire and regulatory bodies determine that a generic version is bioequivalent and safe, it can be approved for market entry.
---
Sources
1. https://www.kerendia.com/
2. https://drugpatentwatch.com/